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Note
Biologics Price Competition and Innovation Act:
Striking a Delicate Balance Between Innovation
and Accessibility
Ude Lu*
The Biologics Price Competition and Innovation Act of
2009 (BPCIA, also known as the Biosimilar Act) was signed
into law in 2010 by President Barack Obama as part of the
healthcare reform bill.1 The central mission of the BPCIA is
two-fold: (1) providing sufficient incentives for continuous
innovations in biologic therapies (i.e., promoting innovation);
and (2) lowering the price of biologic therapies (i.e., promoting
accessibility).2 To promote innovation, the BPCIA provides
twelve-year Food and Drug Administration (FDA) exclusivity to
innovator biologics.3 This twelve-year FDA exclusivity prevents
generic biologics, also known as follow-on biologics (FOBs),
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1. Biologics Price Competition and Innovation Act of 2009, Pub. L. No.
111-148, § 7001, 124 Stat. 119, 804 (2010). The Biologics Price Competition
and Innovation Act (BPCIA) was enacted as part of the Patient Protection and
Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119, 804 (2010).
2. Biologics Price Competition and Innovation Act § 7001(b), 124 Stat. at
804 (“It is the sense of the Senate that a biosimilars pathway balancing
innovations and consumer interests [i.e., accessibility] should be
established.”).
3. Id. § 7002(k)(2)(A), 124 Stat. at 805.
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from being approved.4 To promote accessibility, the BPCIA
provides an abbreviated pathway for FOBs—the abbreviated
biologic license application (ABLA).5 The ABLA allows FOB
manufacturers to cut short the time and the expensive cost of
clinical testing by referring to innovator biologics’ clinical data
to establish safety and efficacy.6
The goal of this Note is to discuss the advantages and
drawbacks of the mechanisms established in the BPCIA and to
suggest modifications to strike a better balance between
innovation and accessibility. Part I of this Note introduces the
legal and scientific background of the BPCIA and HatchWaxman Act in order to engage in further analyses. Part II of
this Note analyzes the competing interests of innovation and
accessibility and suggests a novel six-year data exclusivity and
a six-to-twelve-year market exclusivity regulatory scheme. This
Note concludes that the current design of the BPCIA tips too
favorably toward innovation and compromises accessibility.
The suggested six-year data exclusivity and six-to-twelve-year
market exclusivity regulatory scheme potentially strike a
better balance between innovation and accessibility.
I. BACKGROUND: INTRODUCING THE LEGAL AND
SCIENTIFIC BACKGOUND OF THE BPCIA AND THE
HATCH-WAXMAN ACT
The BPCIA is highly analogous to the Drug Price
Competition and Patent Term Restoration Act introduced in
1984, also known as the Hatch-Waxman Act, which established
4. Id. (stating that the Commissioner of the FDA may not make effective
an approval of a generic biologic until a twelve-year period after the
referenced biologic was approved). Follow-on biologic (FOB) essentially means
the generic version of a biologic pharmaceutical. Agencies, such as the Federal
Trade Commission (FTC), and commentators have adopted the term “follow-on
biologic” to distinguish it from “generic drug” (i.e., a small-molecule drug that
is bioequivalent to a reference small-molecule drug). This is because it is
agreed among scientific communities that it is impossible to make a “generic
biologic” that is bioequivalent to a reference biologic, as one can with smallmolecule drugs. Thus, the term FOB is adopted to emphasize biosimilar and
distinguish from bioequivalent.
5. Id. § 7002, 124 Stat. at 805. Section 7002 was subsequently codified in
42 U.S.C. § 262(k) (defining Licensure of Biological Products (LBP)). LBP is an
abbreviated pathway to get FDA approval on generic versions of biologic
pharmaceuticals. Commentators usually refer to a LBP as an abbreviated
biologic license application (ABLA) in recognition of the highly similar
structure with abbreviated new drug applications (ANDA) established in the
Hatch-Waxman Act.
6. 42 U.S.C. § 262(k) (Supp. V 2011).
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the abbreviated approval process for small molecule drugs.7
Similar to the goals of the BPCIA, the Hatch-Waxman Act tries
to balance two competing interests: innovation and
accessibility.8 To incentivize innovation, the Hatch-Waxman
Act provides patent term extension (PTE) that prolongs the
patent exclusivity period so that innovator companies have an
extended period of market monopoly.9 On the other side of the
scale, to increase public access to drugs, the Hatch-Waxman
Act established an abbreviated new drug application (ANDA) to
introduce competing generic drugs through a fast approval
process.10 The Hatch-Waxman Act establishes the modern
generic drug industry and was incredibly successful in
increasing the accessibility of small molecule drugs.11 In 1984,
when the Hatch-Waxman Act was introduced, generic drug use

7. Drug Price Competition and Patent Term Restoration (HatchWaxman) Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended
in scattered sections of 15, 21, 28, and 35 U.S.C.). The provisions of
abbreviated new drug applications (ANDAs) were subsequently codified in 21
U.S.C. § 355(j). ANDAs are similar to 42 U.S.C. § 262(k) ABLAs. Both ANDAs
and ABLAs allow generic drug companies to reference the clinical data
originally submitted by the innovator drug companies to establish the safety
and efficacy of the generic drugs/biologics. This saves generic drug companies
a tremendous amount of time and money by avoiding full-scale clinical trials
so that generic drugs/FOBs can enter the market quickly after the patent
terms of the innovator drugs expire. One major difference between ANDAs
and ABLAs is that ANDAs regulate small-molecule drugs and ABLAs regulate
biologics.
8. Hatch-Waxman Act, 98 Stat. at 1585 (“To amend the Federal Food,
Drug, and Cosmetic Act to revise the procedures for new drug applications, to
amend title 35, United States Code, to authorize the extensions of the patents
for certain regulated products, and for other purposes.” (emphasis added)).
The “revised procedure” for new drug applications refers to ANDAs. ANDAs
increase drug accessibility by introducing generic drug competition quickly
after the patents covering the reference drug expire. The “extension of patent”
term refers to patent term extension (PTE), which extends the patent term by
50% of the FDA approval time. PTE is to incentivize innovation. See Colleen
Kelly, The Balance Between Innovation and Competition: The Hatch-Waxman
Act, the 2003 Amendments, and Beyond, 66 FOOD & DRUG L.J. 417, 418 (2011).
9. See Hatch-Waxman Act § 201.
10. See Hatch-Waxman Act § 101.
11. Examining the Senate and House Versions of the “Greater Access to
Affordable Pharmaceuticals Act”: Hearing Before the S. Comm. on the
Judiciary, 108th Cong. 7–13 (2003) (statement of Daniel E. Troy, Chief
Counsel, U.S. Food & Drug Administration). The FDA stated that the HatchWaxman Act was working well. Since the Hatch-Waxman Act’s passage in
1984, 10,000 generic drugs have entered the market. By 2003, 50% of the
prescriptions were filled by generic drugs. Id.
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was less than 20% of all prescription drug use.12 By 2010, the
percentage increased to 78%.13 The popularity of generic drugs
drove down small molecule drug prices by an average of almost
75%.14 However, the Hatch-Waxman Act regulates only small
molecule drugs, not biologics.15 This is probably because, as of
1984, biologic pharmaceuticals were still in their infancy.16 In
other words, there was no abbreviated approval process for
biologics before the BPCIA was signed into law in 2010.17
A. SMALL MOLECULE DRUGS V. BIOLOGICS
Biologics are very different from small molecule drugs.
Small molecule drugs are chemically synthesized.18 Biologics

12. Richard G. Frank, The Ongoing Regulation of Generic Drugs, 357 NEW
ENG. J. MED. 1993, 1993 (2007).
13. IMS INST. FOR HEALTHCARE INFORMATICS, THE USE OF MEDICINES IN
THE UNITED STATES: REVIEW OF 2010, at 3 (2011), available at
http://www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Docum
ents/IHII_UseOfMed_report%20.pdf.
14. CONG. BUDGET OFFICE, HOW INCREASED COMPETITION FROM GENERIC
DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL
INDUSTRY 32–33 (1998).
15. Corporate Chronology, GENENTECH, http://www.gene.com/media/
company-information/chronology (last visited Nov. 12, 2013). In modern
biotechnology, recombinant DNA is the major technology used to create
biologics. The first recombinant DNA biologic, human insulin made by
Genentech, was approved by the FDA in 1982, only two years before the
Hatch-Waxman Act was enacted in 1984. Thus, at the time the HatchWaxman Act was enacted, there was no need for an abbreviated pathway for
FOBs, because at that time the innovator biologics are all protected by
patents. See Trader Thoughts, Biogenerics: Not Yet a Reality in the U.S.,
SEEKING ALPHA (Dec. 24, 2007), http://seekingalpha.com/article/58230biogenerics-not-yet-a-reality-in-the-u-s.
16. Corporate Chronology, supra note 15.
17. WENDY H. SCHACHT & JOHN R. THOMAS, FOLLOW-ON BIOLOGICS: THE
LAW AND INTELLECTUAL PROPERTY ISSUES 5 (2012), available at
http://www.fas.org/sgp/crs/misc/R41483.pdf (stating that prior to the
enactment of the BPCIA, there was no generally-applicable abbreviated
statutory pathway for follow-on biologics).
18. 42 U.S.C. § 262(i) (2006 & Supp. V 2011) (“[T]he term ‘biological
product’ means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood,
blood component or derivative, allergenic product, [protein (except any
chemically synthesized polypeptide),] or analogous product, or arsphenamine
or derivative of arsphenamine (or any other trivalent organic arsenic
compound), applicable to the prevention, treatment, or cure of a disease or
condition of human beings.”); see also SCHACHT & THOMAS, supra note 17, at 5
(stating that chemical drugs are based on small molecules that typically
contain dozens of atoms, while biologics are based on macro-molecules that
may consist of millions of atoms).
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are the products of living cells.19 Biologics include: “therapeutic
serums, toxins, antitoxins, vaccines, blood, blood components or
derivatives, allergenic products, proteins, and viruses.”20
Compared to small molecule drugs, biologics have much larger
molecular weights and much more complicated three
dimensional structures.21 Biologics are usually proteins and
antibodies which possess high binding affinity with specific
substrates.22 Unlike small molecule drugs, which usually have
larger tolerance to heat or contamination in the production
process, biologics are extremely heat-sensitive and susceptible
to microbial contamination.23 A minor change in the
manufacturing process, such as a minor change in temperature
of cell culture, can change the overall characteristic of a final
biologic product.24 Thus, quality control for biologics is much
more costly and complex than for small molecule drugs.25
Traditionally, biologics were extracted from animals or
humans bodies.26 This production method is limited in
quantity, and obviously undesirable.27 In 1973, the
development of recombinant DNA technology made mass
production of biologics possible.28 Since then, the medical
19.
20.
21.
22.

SCHACHT & THOMAS, supra note 17, at 5.
42 U.S.C. § 262(i).
See SCHACHT & THOMAS, supra note 17, at 2–3.
Simon D. Roger, Biosimilars: How Similar or Dissimilar Are They?, 11
NEPHROLOGY 341, 343 (2006) (stating that in assessing efficacy of biosimilars,
receptor-binding affinity is an important index).
23. What Are “Biologics” Questions and Answers, FOOD & DRUG ADMIN.,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTob
acco/CBER/ucm133077.htm (last visited Sept. 14, 3013) (“In contrast to most
drugs that are chemically synthesized and their structure is known, most
biologics are complex mixtures that are not easily identified or characterized.
Biological products, including those manufactured by biotechnology, tend to be
heat sensitive and susceptible to microbial contamination. Therefore, it is
necessary to use aseptic principles from initial manufacturing steps, which is
also in contrast to most conventional drugs.”).
24. Michal Nowicki, Basic Facts About Biosimilars, 30 KIDNEY BLOOD
PRESSURE RES. 267, 268 (2007).
25. Id.
26. What Is a Biological Product?, FOOD & DRUG ADMIN.,
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm
(last
visited Sept. 14, 2013).
27. Id.
28. See Biotechnology at 25: The Founders, U. CAL. BERKELEY LIBR.,
http://bancroft.berkeley.edu/Exhibits/Biotech/25.html (last updated May 23,
2000); see also Drug Price Competition and Patent Term Restoration (HatchWaxman) Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended
in scattered sections of 15, 21, 28, and 35 U.S.C.).
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importance of biologics has grown exponentially.29 The FDA
states: “biological products often represent the cutting-edge of
biomedical research and, in time, may offer the most effective
means to treat a variety of medical illnesses and conditions
that presently have no other treatments available.”30
Conditions currently treated by biologics include diseases such
as cancer, arthritis, chronic plaque psoriasis, anemia, and
chronic renal failure.31 Commentators called biologics “the
wonder drug” of the 21st Century.32 In 2007 there were 400
biologics treating more than 200 conditions.33 By 2011, there
were more than 900 biologics in various clinical trial phases
targeting more than 100 diseases.34 There is little doubt that
biologics will make up the majority of pharmaceutical therapies
to treat the most difficult diseases in the future.35
The economic importance of biologics also grew
exponentially in the pharmaceutical industry.36 In 2000,
biologics sales accounted for 11% of all drug sales in the United
States. By 2005, that figure rose to 18%, and by 2010, it grew to
26% of total consumer spending on pharmaceuticals.37

29. Vincent J. Roth, Will FDA Data Exclusivity Make Biologic Patents
Passé? 6 (unpublished manuscript), available at http://works.bepress.com/
context/vincent_roth/article/1000/type/native/viewcontent (“In 2002, biologics
sales accounted for 11% of all U.S. drug sales. By 2006, spending on biologics
totaled $54 billion in the U.S.-approximately 20% of total spending on
pharmaceuticals. By 2010, biologics were estimated at 26% of the total cost of
pharmaceuticals . . . with sales of biologics expected at over $60 billion.”).
30. What Are “Biologics” Questions and Answers, supra note 23.
31. Biologic Medical Product, WIKIPEDIA, http://en.wikipedia.org/wiki/
Biologic_medical_product (last visited Sept. 14, 2013).
32. Zach Patton, Complex Rx: Biologic Meds Are the Wonder Drugs of Our
Time. Can We Afford Them?, GOVERNING, http://www.governing.com/
topics/politics/Complex-Rx.html (last visited Oct. 20, 2013).
33. Id.
34. Grady Forrer, 900 New Medicines in Development Show the
Biotechnology Medical Revolution Is Going Strong, CATALYST (Sept. 14, 2011,
11:18 AM), http://www.phrma.org/catalyst/900-new-medicines-developmentshow-biotechnology-medical-revolution-going-strong/.
35. See What Are “Biologics” Questions and Answers, supra note 23
(stating that biologics represent the forefront of biomedical research and may
be used to treat a variety of medical conditions for which no other treatments
are available).
36. Id.
37. Nowicki, supra note 24, at 267.
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B. THE URGE FOR BIOSIMILARS BEFORE 2010
During 2003 and 2004, patents protecting several multibillion dollar sale biologics expired.38 Yet innovator companies
faced no market competition because, at that time, there was
no abbreviated pathway to approve FOBs.39 Since then, there
has been increasing pressure on Congress to provide for an
abbreviated approval pathway (i.e., biosimilar pathway, similar
to ANDA in the Hatch-Waxman Act to approve FOBs).40 The
pressure on Congress intensified after both the European
Union (EU) and Canada implemented their versions of
biosimilar pathways in 2004 and 2006 respectively.41 In 2004,
Dr. Carole Ben-Maimon, President of Barr Research, Inc.,
testified in front of the Senate Judiciary Committee: “[G]eneric
competition for biotech pharmaceuticals has the potential to
offer consumers dramatic and substantial savings, while also
lowering America’s healthcare bill.”42 Kathleen Jaeger, the

38. Trader Thoughts, supra note 15 (“Patent for Biogen’s Avonex (2006
sales: $1Bn) expired in 2003, Eli Lilly’s Humatrope ($390M) expired in 2003,
Genentech’s Humulin ($1Bn) expired in 2004, while the blockbuster anemia
drug—Amgen’s Epogen ($2.5 Bn) is set to expire in 2012.”).
39. See SCHACHT & THOMAS, supra note 17, at 5 (stating that prior to the
enactment of the BPCIA in 2010, there was no generally applicable
abbreviated statutory pathway for FOBs); see also What We Do, DRAGONFLY
SCIENCES,
http://www.dragonflysciences.com/whatWeDo/index.html
(last
visited Mar. 30, 2013) (stating that monoclonal antibody (mAB)
manufacturers (mAB is a kind of biologic) have enjoyed market monopoly due
to both patent protection and the lack of regulatory mechanisms to approve
generic versions of biologics).
40. ROBERT J. SHAPIRO ET AL., THE POTENTIAL AMERICAN MARKET FOR
GENERIC BIOLOGICAL TREATMENTS AND ASSOCIATED COST SAVINGS 1, 2 (2008)
available
at
http://www.sonecon.com/docs/studies/0208_
GenericBiologicsStudy.pdf. (“Congress created an accelerated regulatory
process for FDA approval of generic pharmaceuticals in 1984, under the
Hatch-Waxman Act, but the law covers only traditional, small-molecule
pharmaceuticals and not biologics.”); see also Gregory N. Mandel, The Generic
Biologics Debate: Industry’s Unintended Admission that Biotech Patents Fail
Enablement, 11 VA. J.L. & TECH., Fall 2006, at 1 (“[Generic] manufacturers
currently are significantly limited in their ability to sell generic copies of
biologics even after the pioneer biologic patents expire. As early biologics are
starting to go off-patent, this regulatory mix-up is having a notable impact on
the availability of biologics and raising the cost of health care.”).
41. Noel Courage & Ainslie Parsons, The Comparability Conundrum:
Biosimilars in the United States, Europe and Canada, 66 FOOD & DRUG L.J.
203, 209–12 (2011).
42. Law of Biologic Medicine: Hearing Before the S. Comm. of the
Judiciary, 108th Cong. 24–25 (2004) (statement of Carole Ben-Maimon, M.D.,
President and Chief Operating Officer, Barr Research, Inc., Bala Cynwyd,
Pennsylvania).
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president of the Generic Pharmaceutical Association stated in
2005: “Sound science already has enabled citizens in the
European Union, Australia, India and South America to have
access to these medicines. And, the EU estimates that it will
save $2.8 billion from the market entry of just a few
products . . . . Clearly, the U.S. must stop dragging its feet.”43
In 2009, President Obama also urged Congress to act on a
biosimilar pathway: “[W]e need to introduce generic biologic
drugs into the marketplace . . . . But right now, there is no
pathway at the FDA for approving generic versions of these
drugs.”44
C. DATA EXCLUSIVITY V. MARKET EXCLUSIVITY
The BPCIA’s mission is to promote both innovation and
accessibility of biologics.45 In striking the balance, the key point
is how long of a period of exclusivity the FDA should provide
for innovator biologics.46 Currently, the BPCIA provides a
twelve-year FDA exclusivity for a new biologic entity (NBE).47
A further question is whether this twelve-year exclusivity is
data exclusivity or market exclusivity. The statute is currently
unclear on this.48

43. Kathleen Jaeger, President & CEO, GPhA, Speech at the Windhover
FDA/CMS Summit (Dec. 5, 2006), available at http://gpha.hfwebdev.com/
resources/2006/12/04/gpha-speech-windhover-fdacms-summit.
44. President Barack Obama, Address to the American Medical
Association
in
Chicago
(June
15,
2009),
available
at
http://www.huffingtonpost.com/2009/06/15/obama-ama-speech-fulltex_n_215699.html.
45. See Biologics Price Competition and Innovation Act of 2009, Pub. L.
No. 111-148, § 7001(b), 124 Stat. 119, 804 (2010).
46. Lewis Krauskopf, Teva Executive Upbeat on Biogenerics in 2009,
REUTERS (Dec. 23, 2008), http://uk.reuters.com/article/2008/12/23/businessprous-teva-idUKTRE4BM4OA20081223 (noting the key point in the legislation of
the FOB pathway is the amount of exclusivity that would be afforded to
brand-name biotech drugs; generic drug makers like Teva want to limit it to
seven years, while the brand name companies want fourteen years). Teva is
the biggest generic drug company in the world, headquartered in Israel,
having 46,000 employees, running annual revenue more than $20 billion in
2012. About Us, TEVAPHARM.COM, http://www.tevapharm.com/About/Pages/
AboutUs.aspx (last visited Oct. 10, 2013).
47. 42 U.S.C. § 262(k)(7)(A) (Supp. V 2011).
48. Margo Bagley, Patent Term Restoration and Non-Patent Exclusivity in
the United States 22 (Univ. of Va. Sch. of Law, Public Law and Legal Theory
Research Paper Series, No. 2011-25, 2011), available at http://ssrn.com/
abstract=1899533.
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The contrast between data and market exclusivity has
significant implications for the general public.49 Data
exclusivity prohibits FOB manufacturers from relying on the
clinical trial data submitted by the innovator companies.50
Notice that, by definition, ABLA is a regulatory pathway
allowing FOB manufacturers to rely on innovators’ clinical data
to establish safety and efficacy.51 Thus, if the twelve-year
exclusivity is a data exclusivity, it essentially means ABLA is
not available to FOB manufactures during the first twelve
years after a reference biologic is approved.52 Market
exclusivity, as opposed to data exclusivity, does not prohibit the
FDA from accepting and reviewing an ABLA.53 Market
exclusivity merely prohibits the FDA from approving an FOB
to sell on the market.54 In other words, the FDA can accept and
review an ABLA but will not approve it until the applicable
market exclusivity expires.55
Years of delay in introducing drug price competition equal
to the FDA review period of FOBs is the difference between a
data or market exclusivity.56 This delay of drug price
49. See Kurt R. Karst, Tussle Over BPCIA “Market” Versus “Data”
Exclusivity Continues; This Time the Generic Supporters Chime in, FDA L.
BLOG (Jan. 21, 2011, 6:38 AM), http://www.fdalawblog.net/fda_law_blog_
hyman_phelps/2011/01/tussle-over-bpcia-market-versus-data-exclusivitycontinues-this-time-the-generics-side-chimes-in.html (asserting that generic
supporters argue that interpreting the twelve-year FDA exclusivity as a data
exclusivity, which prevents biosimilar (i.e., ABLA) submission has serious
consequences and that consumers will have to endure an unknown period of
delay of FDA review and approval that could stretch far beyond the twelveyear total that was set in the legislation).
50. See Bagley, supra note 48, at 14 (noting that the five-year data
exclusivity period for a new chemical entity (NCE) prevents generic drug
companies from even filing an ANDA).
51. 42 U.S.C. § 262(k)(2)(A) (stating that the biological product can
establish biosimilarity to a reference product based upon data derived from
analytical studies, animal studies, and clinical studies).
52. See Bagley, supra note 48, at 22.
53. See id. at 15–18 (explaining market exclusivity within the context of
pediatric testing exclusivity and orphan drug exclusivity). Market exclusivity
does not prevent generic companies from filing an ANDA, as in data
exclusivity. During the market exclusivity period, the FDA can receive and
review an ANDA but will not approve it until the reference drug’s market
exclusivity expires.
54. Id.
55. Id.
56. See Karst, supra note 49 (stating that data exclusivity which prevents
ABLA submission stretches the market monopoly far beyond the twelve-year
period); see also infra note 242 (establishing that a reasonable expectation for
the FDA to approve an ABLA is about three to four years).
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competition in biologics translates to tens of billions of medical
expenses to the general public.57
D. BIOSIMILAR V. INTERCHANGEABLE
The BPCIA provides two categories of FOBs: (1) biosimilar,
defined in 42 U.S.C. § 262 (k)(2); and (2) interchangeable,
defined in 42 U.S.C. § 262 (k)(4).58 An FOB is biosimilar to a
referenced biologic if the FOB (1) shows sufficient similarity
through analytical, animal, and clinical studies; (2) utilizes the
same therapeutic mechanism; (3) is used for the same
indications; (4) uses the same drug administration and dosages;
and (5) the quality control of the manufacture facility of the
FOB assures safety, purity, and potency.59 An FOB is
interchangeable with a referenced biologic, if it is (1)
biosimilar; (2) expected to produce the same clinical result as
reference drug in any given patient; and (3) the risk of
switching between the FOB and reference drugs is not greater
than the risk of continuous use of the reference drug.60 If an
FOB is biosimilar, it has to be prescribed by the medical doctor;
on the other hand, if an FOB is interchangeable, it can be
switched by a pharmacist without informing the patient or the
prescribing doctor.61

57. Saurabh Aggarwal, What’s Fueling the Biotech Engine—2011 to 2012,
30 NATURE BIOTECHNOLOGY 1191, 1192 (2012) (showing that the annual sales
of biologics was (in billions USD) $44.5 in 2007, $46.5 in 2008, $48.2 in 2009,
$51.3 in 2010, and $53.8 in 2011). From the experience of small-molecule
drugs, the price of a brand-name drug drops 50% instantly in the first year of
the introduction of generic drug competition. Applying this dropping rate to
biologics means the general public can save around $20 billion to $25 billion
each year through drug-price competition, assuming each innovator biologic
has an FOB competitor.
58. 42 U.S.C. § 262(k) (Supp. V 2011).
59. § 262(k)(2).
60. § 262(k)(4).
61. § 262(i)(3) (“The term ‘interchangeable’ or ‘interchangeability’, in
reference to a biological product that is shown to meet the standards described
in subsection (k)(4), means that the biological product may be substituted for
the reference product without the intervention of the health care provider who
prescribed the reference product.”).
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II. ANALYSIS: PROMOTING INNOVATION AND
ACCESSIBILITY
A. PROMOTING INNOVATION
The general public benefits from the innovation of new
biologics because they provide life-quality improving
treatments that did not exist before.62 It is important for the
government to offer proper incentives to insure innovator drug
companies in recouping the heavy investments and ensure
their ability to fund new research to continue innovation.63
Commentators view the twelve-year FDA exclusivity provided
in 42 U.S.C. § 262(k)(7)(A) to be the most important and
effective measure in the BPCIA to promote innovation.64
This twelve-year FDA exclusivity is complementary to,
independent from, and even stronger than patent exclusivity.65
There are four reasons to support these assertions. First, this
NBE exclusivity de facto covers more than one patent.66 The
FDA grants this exclusivity on each new biological entity,
which covers 2.7 patents on average.67 Second, this twelve-year
exclusivity is likely to last longer than the active patent life
62. See Patton, supra note 32 (stating that biologics are the wonder drugs
of this age, promising to treat AIDS, cancer, Alzheimer’s, and multiple
sclerosis).
63. Henry Grabowski, Follow-On Biologics: Data Exclusivity and the
Balance Between Innovation and Competition, 7 NATURE REVIEWS DRUG
DISCOVERY 479, 486 (2008) (stating that developing a new biologic entity costs
around $1.24–$1.33 billion, and the cost has to be recouped from the sales of
approved product).
64. Don Ware & Nick Littlefield, FOLLOW-ON BIOLOGICS AND PATENT
REFORM: WILL THEY DISCOURAGE VENTURE CAPITAL INVESTMENT IN THE
BIOTECHNOLOGY INDUSTRY? 5 (2009), available at http://www.foleyhoag.com/
publications/ebooks-and-white-papers/2008/june/follow-on-bioligics-andpatent-reform (“One of the issues of greatest importance involves the number
of years of data exclusivity provided for a licensed biological product. ‘Data
exclusivity’ refers to a period of time during which an FOB applicant is
precluded from relying on clinical data from the innovator product as evidence
of safety and effectiveness. Too short an exclusivity period could serve as a
serious deterrent for VC investors if they believe the risk of early market
entry of a biosimilar product will reduce the profitability of the branded
compound. The loss of VC funding would seriously hinder, if not destroy,
biotechnology innovation.”).
65. Grabowski, supra note 63, at 480 (stating that data exclusivity
provides an important back-up to the patent system).
66. C. Scott Hemphill & Bhaven N. Sampat, Evergreening, Patent
Challenges, and Effective Market Life in Pharmaceuticals, 31 J. HEALTH
ECON. 327, 330 (2012).
67. Id.
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during which innovator companies recoup their investments.68
Third, FDA exclusivity is independent from patent
exclusivity.69 Even if the patents covering the biologic are
invalidated, the FDA exclusivity still stands.70 Fourth, FDA
exclusivity practically eliminates the design-around issues.71
Innovator companies often rely on method patents to protect
the manufacturing process of the final products.72 These
method patents are relatively easy to design around.73 FDA
exclusivity prevents design-around because FDA exclusivity
protects the final product, regardless of how it is
manufactured.74 Even if a generic company develops a different
manufacturing process to make the same biologic that does not
infringe the innovator companies’ patents, the final product is
still precluded from FDA approval.75
The importance of using FDA exclusivity in promoting
innovation can be further analyzed in three different
perspectives: cost of capital and time in research and
development, patent uncertainty, and drops in new drug
applications.

68. Linfong Tzeng, Follow-on Biologics, Data Exclusivity, and the FDA, 25
BERKELEY TECH. L.J. 135, 156 (2010) (stating that the twelve-year exclusivity
runs potentially longer than patent protection). A detailed calculation is
provided later in this Note showing that this twelve-year exclusivity lasts
longer than an average, remaining active patent term of a biologic.
69. Id. (explaining that FDA exclusivity is independent from patent
exclusivity and stating that “[t]his is potentially troubling as data exclusivity
is unchallengeable in court” (emphasis added)). Whether the FDA decision in
granting data exclusivity is challengeable is a complex legal issue in
administrative law, which is out of the scope of this Note. My research shows
that there is indeed no judicial challenge to an FDA decision granting data
exclusivity.
70. Id.
71. See id. at 154–55.
72. See Hemphill & Sampat, supra note 66, at 330.
73. BIOTECH. INDUSTRY ORG., FTC BIOSIMILARS REPORT REBUTTAL
(2009), available at http://www.bio.org/sites/default/files/FTC_biosimilars_
report_rebuttal.pdf (stating that patents covering biologics are often narrower
and easier to “design around” than those of small-molecule drugs, and
innovator companies need additional data exclusivity to secure their market
monopolies).
74. See Tzeng, supra note 68, at 154–55.
75. Id.
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1. Cost of Capital and Time in Research and Development
The cost to bring a biologic drug to the market is higher
than that for a small-molecule drug.76 This higher cost is partly
due to the high manufacture quality required in making a
biologic.77
Any minor change in the manufacture or drug-delivery
process can change the overall characteristic of a final biologic
product.78 For example, with exactly the same manufacturing
process, a manufacturer of interferon beta-1a produced two
batches
of
products
with
drastically
different
immunogenicity.79 One batch was safe and effective, yet
another batch caused serious immune responses.80 The only
difference between the two batches was the manufacture site.81
The manufacturing conditions that affect the properties of
biologics generally include: the cell lines used to produce the
biologics,
culture/fermentation
conditions,
purification
procedures, and container closure/packaging systems.82 Thus, a
much higher quality control standard is required for biologics
than for small molecule drugs.83 This high quality standard
translates to higher capital investment in research and
76. Joseph A. DiMasi & Henry G. Grabowski, The Cost of
Biopharmaceutical R&D: Is Biotech Different?, 28 MGMT. & DECISION ECON.
469, 477 (2007) (showing that, on average, it costs $1.24 billion to bring a
biologic to the market compared to $899 million for a small-molecule drug).
77. FDA, SCIENTIFIC CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY
TO
A
REFERENCE PRODUCT 5–6 (2012) [hereinafter SCIENTIFIC
CONSIDERATIONS],
available
at
http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
(stating that different cell lines, raw materials, equipment, processes, process
controls, and acceptance criteria are all likely to affect the quality of produced
biologics).
78. See Nowicki, supra note 24, at 268.
79. Sungae S. Park et al., Biochemical Assessment of Erythropoietin
Products From Asia Versus US Epoetin Alfa Manufactured by Amgen, 98 J.
PHARMACEUTICAL SCI. 1688, 1689 (2009). Biologics are proteins. The folding
process of a protein is highly sensitive to environmental conditions (e.g.,
temperature, ion concentration, virus/bacteria contamination, etc.). A protein
that is properly folded (i.e., having a proper three-dimensional structure) can
be an effective drug. In contrast, the same protein that is not properly folded
can cause serious immune response and death.
80. Id.
81. Id.
82. Id.
83. SCIENTIFIC CONSIDERATIONS, supra note 77, at 4 (stating that even
minor structural differences, including certain changes in glycosylation
patterns, can significantly affect a protein’s safety, purity, and potency). It will
be important to evaluate these differences.
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development.84 In addition, the sensitive nature of biologics
results in a longer period of clinical trial and regulatory
review.85 The average period of clinical trial and regulatory
review for a biologic is 97.7 months, which is 7 months longer
than for a small-molecule drug.86
Higher manufacturing cost translates to higher drug price,
which consequently reduces the market demand.87 This
reduction of market demand negatively impacts the
profitability of innovator companies.88 Longer clinical trials and
regulatory review periods mean a shorter active patent life to
recoup the investment.89 This also negatively impacts the
innovator companies’ profitability. The twelve-year FDA
exclusivity provided in the BPCIA might be justified as
increasing the profitability of innovator companies (i.e.,
providing a long enough monopoly period so that innovator
companies can recoup their investments and continue to
innovate).90
2. Patent Uncertainty
Patent uncertainty seriously affects the profitability of
innovator drug companies.91 Generic drug companies are in an
advantageous position in patent-invalidity challenges and have

84. Compare Grabowski, supra note 63, at 480 (showing that in oncology,
the area with the greatest concentration of biological entities, the mean cost is
“US$1.016 billion compared with $868 million” in small-molecule drugs), with
DiMasi & Grabowski, supra note 76, at 477.
85. DiMasi & Grabowski, supra note 76, at 473; Grabowski, supra note
63, at 481.
86. Grabowski, supra note 63, at 481.
87. Id. at 482 (“This [higher development cost of biologics] reflects the
need to resolve novel manufacturing challenges at the R&D stage. By
contrast, manufacturing process issues in R&D are typically more
straightforward for drugs based on chemical synthesis [i.e., small-molecule
drugs].”).
88. Id.
89. Id. at 481–82. Because patent protection is a fixed term (i.e., twenty
years from filing), the longer it takes for a drug to hit the market, the less
patent term left to recoup the investment.
90. See 42 U.S.C. § 262(k)(7)(A) (Supp. V 2011).
91. Matthew J. Higgins & Stuart J. H. Graham, Balancing Innovation
and Access: Patent Challenges Tip the Scales, 326 SCI. 370, 370 (2009) (“The
Congressional Budget Office estimated that increased competition from
generic drugs resulted in a 12% loss in revenues on sales of brand-name
drugs . . . . [The patent invalidity] challenges diminish [brand-name company]
revenues and profits, contributing to the current crisis in industry R&D
pipelines.”).
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strong incentives to file such challenges.92 In addition, current
developments in patent law make the invalidation of
biotechnology-related patents especially easy.93 The twelveyear FDA exclusivity provides a complementary protection to
this patent vulnerability, because FDA exclusivity is a
monopoly power independent of patent protection.94 In other
words, even if the patents covering the innovator drugs or
biologics were invalidated, the granted FDA exclusivity is
unaffected.
Recent Federal Circuit decisions further weaken the
already vulnerable patents owned by innovator companies by
imposing
particularly
stringent
patent
disclosure
requirements.95 The Federal Circuit decisions imply that if a
field of art is more predictive, such as mechanical engineering
and software programming, less disclosure is required to fulfill
the written description and enablement requirements.96 On the
contrary, if the field of art is less predictive, such as chemistry
or biotechnology, more disclosure is required.97 Recently, many
92. See FTC, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION: AN
FTC STUDY, at viii (2002), available at http://www.ftc.gov/os/2002/07/
genericdrugstudy.pdf (“[G]eneric applicants prevailed in nearly 75% of the
patent litigation ultimately resolved by a court decision.”); see also Higgins &
Graham, supra note 91, at 370 (suggesting that generic companies have
incentives to bring patent invalidity challenges, because the costs of
challenging a patent are relatively small, i.e., “$5 million compared with the
large average potential payoff of $60 million in the first 180 days alone”).
93. See Dan L. Burk & Mark A. Lemley, Is Patent Law TechnologySpecific?, 17 BERKELEY TECH. L.J. 1155, 1173–82 (2002) (noting that the
Federal Circuit has adopted a particularly stringent disclosure standard for
patenting macromolecules (i.e., biologics)). This heightened 35 U.S.C. § 112
“written description” requirement ends up becoming the legal ground for
invalidating many biotechnology and chemical patents. Id.
94. See Grabowski, supra note 63, at 480 (stating data exclusivity
provides an important back-up to the patent system in cases where the
patents could be invalidated).
95. See Burk & Lemley, supra note 93, at 1173 (“In contrast to the
Federal Circuit decisions regarding software, recent decisions involving
genetic material have imposed a stringent disclosure standard for patenting
macromolecules.”).
96. Id. at 1157; e.g., N. Telecom, Inc. v. Datapoint Corp., 908 F.2d 931,
942 (Fed. Cir. 1990) (“‘The computer language is not a conjuration of some
black art, it is simply a highly structured language . . . . [T]he conversion of a
complete thought (as expressed in English and mathematics, i.e. the known
input, the desired output, the mathematical expressions needed and the
methods of using those expressions) into a language a machine understands is
necessarily a mere clerical function to a skilled programmer.’” (quoting In re
Sherwood, 613 F.2d 809, 817 n.6 (C.C.P.A. 1980))).
97. Burk & Lemley, supra note 93, at 1157.
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biotechnology patents have been invalidated because of these
stringent requirements.98 In addition, the safe harbor created
by the Hatch-Waxman Act in patent law, 35 U.S.C. § 271,
significantly strengthens generic companies’ legal positions in
patent-invalidity challenges by creating an exemption for
generic drug companies that conduct research on patentprotected reference drugs with the intention to gain FDA
approval.99 This allows generic companies to gain thorough,
hands-on knowledge regarding the targeted reference drugs
and strengthens generic companies’ legal theories in patentinvalidity challenges.100

98. E.g., Fiers v. Revel, 984 F.2d 1164, 1170–71 (Fed. Cir. 1993). The
Federal Circuit invalidated a biologic patent, which disclosed methods for
isolating a fragment of the DNA sequence coding for β–IF, a biologic, and for
isolating messenger RNA coding for β–IF. Id. at 1167, 1170. The invalidation
was largely based on the fact that Revel did not describe the actual sequence
of the DNA at issue, id. at 1170–71, even if transferring an RNA sequence to
DNA sequence is considered merely a mechanical routine that involves no
technical challenge. See Reverse Transcriptase Enzymes, LIFE TECHNOLOGIES,
http://www.lifetechnologies.com/us/en/home/life-science/pcr/reversetranscription/reverse-transcriptase-enzymes.html (last visited Sept. 15, 2013)
(listing an enzyme cost per reaction as low as $1.15); see also Regents of the
Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1575 (Fed. Cir. 1997). The
Federal Circuit invalidated a patent which claimed human insulin DNA but
only disclosed rat insulin DNA, id. at 1567–68, disregarding that the research
methods used in sequencing rat and human are exactly the same and that rat
and human DNA sequences are 95% identical. See Nonconfidential Brief for
Defendant-Appellee Eli Lilly & Co. at 43, Regents of the Univ. of Cal. v. Eli
Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997) (No. 96-1175), 1996 WL 33419502
(“The trial evidence established that a change in only four nucleotides of
the rat DNA sequence would have yielded a sequence capable of producing
human insulin.”).
99. 35 U.S.C. § 271(e)(1) (2006 & Supp. V 2011). The safe harbor excuses
generic drug companies from patent infringement in conducting otherwise
infringing acts in relation to FDA submissions. Section 271(e)(1) states:
It shall not be an act of infringement to make, use, offer to sell, or sell
within the United States or import into the United States a patented
invention . . . solely for uses reasonably related to the development
and submission of information under a Federal law which regulates
the manufacture, use, or sale of drugs or veterinary biological
products.
Id. (emphasis added). It should be noted that this safe harbor provision
language is general and covers both small-molecule drugs and biologics.
100. See generally Paragraph Four Explained, PARAGRAPHFOUR.COM,
http://www.paragraphfour.com/explained/why_challenge.html (last visited
Sept. 15, 2013) (describing the incentives that the Hatch-Waxman Act
provides to generic companies).
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Generic drug companies have strong incentives to
challenge innovator companies’ patents.101 The Hatch-Waxman
Act provides five-year data exclusivity to new chemical entities,
during which generic drug companies cannot submit an ANDA
referring to the patented drug’s clinical data.102 However, there
is an exception that can shorten data exclusivity by one year.103
An ANDA can be submitted at the end of the fourth year if the
ANDA is submitted under 21 U.S.C. § 355(j)(5)(B)(iv), which
commences a patent-invalidation challenge.104 The first
approved generic drug submitted under Paragraph IV is
entitled to 180-day market exclusivity.105 During this market
exclusivity period, the FDA will not approve another ANDA
application (i.e., during this 180 days, the successful
challenger’s generic drug will be the only generic drug on the
market).106 This 180-day market exclusivity provides generic
drug companies with strong incentives to challenge innovator
drug patents.107 Indeed, patent-invalidation challenges
commenced under Paragraph IV ANDA submissions generally
increased in the past decade.108 The BPCIA provides similar
mechanisms for FOB companies to raise patent-invalidation
101. See Higgins & Graham, supra note 91, at 370 (suggesting generic
companies have an incentive to bring patent-invalidity challenges).
102. 21 U.S.C. § 355(c)(3)(E)(ii) (2012). The statute provides:
[N]o application [i.e., ANDA] . . . may be submitted . . . before the
expiration of five years from the date of the approval of the
application under subsection (b) of this section [i.e., the approved
reference drug], except that such an application [i.e., ANDA] may be
submitted under subsection (b) of this section after the expiration of
four years from the date of the approval of the subsection (b)
application if it contains a certification of patent invalidity or
noninfringement described in clause (iv) of subsection (b)(2)(A) of this
section [i.e., paragraph IV challenge].
Id. (emphasis added). In sum, that statute specifically prevents a generic
company from submitting an ANDA during the five-year data exclusivity
period.
103. § 355(b)(2)(A)(iv). An ANDA submitted under § 355(b)(2)(A)(iv), also
known as a Paragraph IV submission, includes a patent-invalidation
challenge. Higgins & Graham, supra note 93, at 370. This provision states:
“such patent is invalid or will not be infringed by the manufacture, use, or sale
of the new drug for which the application is submitted.” § 355(b)(2)(A)(iv).
104. § 355(j)(5)(B)(iv).
105. § 355(j)(5)(B)(iv)(I). This provision incentivizes generic companies to
challenge weak patents. See FTC, supra note 92.
106. § 355(j)(5)(B)(iv)(I).
107. See FTC, supra note 92.
108. Higgins & Graham, supra note 91, at 370 (displaying the number of
Paragraph IV challenges (counts): 35 in 2001, 33 in 2002, 96 in 2003, 90 in
2004, 81 in 2005, 87 in 2006, 162 in 2007, and 165 in 2008).
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challenges.109 This ever-increasing number of patentinvalidation challenges denotes that innovator drug companies
suffer a high level of patent uncertainty, which drastically
decreases the profitability of innovator drugs.110 Fosamax, a
popular osteoporosis drug made by Merck that generates $3
billion in annual sales, illustrates clearly the serious economic
damages caused by patent uncertainty.111 Teva, the largest
generic drug company in the world,112 brought an invalidation
challenge under Paragraph IV and successfully invalidated
Fosamax patents about four years before they were due to
expire.113 Fosamax’s sales drastically decreased in the
subsequent year of 2008 from $3 billion to $1.5 billion.114 In
addition, Teva alone had 160 pending ANDAs in 2007,
including 92 Paragraph IV challenges, which put at risk over
$100 billion in sales.115
The Federal Trade Commission (FTC) reported that
generic companies prevailed in 75% of patent-invalidation
challenges,116 while the challenge success rate across all
technical fields was at 52%.117 This patent uncertainty
seriously affects innovator drug companies’ ability to fund the

109. 42 U.S.C. § 262(l)(3)(B)(ii)(I) (Supp. V 2011). The statute states:
[An ABLA] applicant [e.g., an FOB company] shall provide to the
reference product sponsor [i.e., innovator company] . . . a detailed
statement that describes, on a claim by claim basis, the factual and
legal basis of the opinion of the subsection (k) applicant [i.e., the FOB
company] that such patent is invalid, unenforceable, or will not be
infringed by the commercial marketing of the biological product that
is the subject of the subsection (k) application.
Id.
110. Higgins & Graham, supra note 91, at 370.
111. Id. at 370–71.
112. Kathlyn Stone, Top Generic Drug Companies, ABOUT.COM PHARMA,
http://pharma.about.com/od/Generics/a/Top-Generic-Drug-Companies.htm
(last visited Sept. 15, 2013).
113. Higgins & Graham, supra note 91, at 371.
114. Id.
115. Id.
116. See FTC, supra note 92.
117. PRICEWATERHOUSECOOPERS, A CLOSER LOOK: 2008 PATENT
LITIGATION STUDY: DAMAGES AWARDS, SUCCESS RATES AND TIME-TO-TRIAL 10
(2008), available at http://www.pwc.com/en_us/us/forensic-services/assets/
2008_patent_litigation_study.pdf. The PricewaterhouseCoopers report shows
that, across all technical fields, 52% of the patent invalidations in which the
alleged infringer is the plaintiff are successful. In contrast, the FTC reported
that 75% of litigated biotechnology patents are declared invalid. This suggests
that biotech patents are particularly vulnerable to patent-invalidity
challenges.
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research for new drugs.118 Many commentators argue that
extended FDA exclusivity is necessary to promote innovation
because it is independent from patent exclusivity and stays
effective regardless of the validity of the covering patents.119
3. Decrease in New Drug Applications
The annual number of new drug applications generally
decreased in the past fifteen years,120 despite significant
development in biological science and technology.121
Science and technology in the biomedical field has hugely
advanced in the past sixty years.122 For example, during the
1980s to 1990s, the number of drug candidates that could be
synthesized by an individual chemist in a year increased 800fold.123 The speed of DNA sequencing increased a billion times
since 1970.124 The time required to deduce a protein structure
via X-ray diffraction decreased more than a thousand times.125
Despite the advancement of technology, the number of new
drugs approved per $1 billion spent on research and
development has decreased by half every nine years since
1950.126 This rate of decrease falls short roughly eighty-fold in
inflation-adjusted terms.127 The average number of new drugs
approved each year between 1995 and 1999 was 37.6. The
number decreased to 30.0 during 2000–2004, and the number
dropped to 20.2 during 2005–2009.128

118. See Higgins & Graham, supra note 91, at 371 (“Economic research
shows that there is a [pharmaceutical] market failure . . . .”).
119. Id. at 371; see also Grabowski, supra note 63, at 479. Contrary to the
uncertainty inherent in the patent system, FDA exclusivity provides a defined
period of monopoly with absolute certainty.
120. Cf. Is It True FDA Is Approving Fewer New Drugs Lately?, FOOD &
DRUG ADMIN., http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/
UCM247465.pdf (last visited Sept. 16, 2013) (displaying charts outlining the
steady decrease of new molecular entity applications from 1996–2010).
121. Jack W. Scannell et al., Diagnosing the Decline in Pharmaceutical
R&D Efficiency, 11 NATURE REVIEWS DRUG DISCOVERY 191, 191 (2012).
122. Id.
123. Id.
124. Id.
125. Id.
126. Id.
127. Id.
128. K.I. Kaitin & J.A. DiMasi, Pharmaceutical Innovation in the 21st
Century: New Drug Approvals in the First Decade, 2000–2009, 89 CLINICAL
PHARMACEUTICALS & THERAPEUTICS 183, 185 (2011).
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Commentators have suggested many possible reasons that
explain the constant decrease of innovation in the
pharmaceutical industry.129 One explanation is that in vitro
experiments conducted in the laboratory are not necessarily
repeatable in humans, meaning the basic research is performed
without benefiting the medical industry.130 Another
explanation is the “low-hanging fruit” theory: fruit that hangs
lower will get picked first. This is saying the relatively easier
medical problems have been solved earlier, and what remains
today are issues that are more difficult.131 Another explanation
is it is harder to develop a better new drug.132 If a new drug is
not better than existing therapies, the drug will likely be
abandoned because the marginal profit does not justify the
investments.133
The explanations provided by commentators are
speculative in nature and hard to verify.134 However, it is a fact
that the number of approved new drugs has decreased steadily
in the past two decades.135 This steady decrease in innovation
may justify twelve-year FDA exclusivity136 that provides a
longer period of market monopoly and a higher profit margin
for innovator drug companies.137

129. E.g., Scannell et al., supra note 121, at 193–97. Scannell et al.
introduced several different theories to explain the drop in innovation,
including: the “better than the Beatles” problem, the “cautious regulator”
problem, the “throw money at it” tendency, and the “basic research bruteforce” bias. Id. at 193. Yet Scannell et al. admit that none of the theories are
conclusive.
130. David F. Horrobin, Modern Biomedical Research: An Internally SelfConsistent Universe with Little Contact with Medical Reality?, 2 NATURE
REVIEWS DRUG DISCOVERY 151, 152 (2003).
131. Id. at 151.
132. See Scannell et al., supra note 121, at 193 (“An ever-improving back
catalogue of approved medicines increases the complexity of the development
process for new drugs, and raises the evidential hurdles for approval, adoption
and reimbursement.”).
133. Id. (“[T]he fruit [the authors’ metaphor for pharmaceutical drugs] that
has been picked reduces the [average] value of the fruit that is left in the
tree.”).
134. See id. at 198. By suggesting possible reasons to explain the steady
decrease in new drug applications, Scannell et al. wanted to “provoke further
analysis.”
135. Kaitin & DiMasi, supra note 128, at 185.
136. 42 U.S.C. § 262(k)(7)(A) (Supp. V 2011).
137. Cf. Higgins & Graham, supra note 91, at 371 (“A robust system of
market innovation is built on financial incentives.”).
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B. PROMOTING ACCESSIBILITY
New biologics promise cutting edge therapies for the
toughest diseases faced in our time.138 However, there will be
no meaningful benefit to society if these therapies are
prohibitively expensive and not accessible to the general
public.139
Unfortunately, many biologic therapies are prohibitively
expensive.140 Biologics on average cost twenty times more than
small-molecule drugs.141 For example, Enbrel, an anti-arthritis
biologic, costs $20,000 per year, compared to $300 per year for
the most expensive small-molecule drug treatment for
arthritis.142 Treating breast cancer with a year’s worth of the
biologic Herceptin can cost $48,000.143 Remicade, a biologic
treatment for rheumatoid arthritis costs $20,000 a year.144
Cerezyme, a treatment for a rare genetic disorder, Gaucher
disease, which causes fatty deposits to build up in certain
organs and bones, costs $200,000 to $300,000 per year.145 From
1998 to 2006, the overall costs for biologics went up 505%,
according to Kaiser Permanente.146 The overall sales of
biologics reached around $100 billion in 2010, representing
26% of the total cost of pharmaceuticals.147
The ABLA aims to replicate the successful experience of
ANDA to lower the drug price by introducing market
138. See Patton, supra note 32 (stating that biologics are the “wonder
drugs” of our age because they promise to treat AIDS, cancer, Alzheimer’s, and
multiple sclerosis).
139. Victoria Colliver, Priced Out of Pain Relief: Insurers Balk at High
Costs of Promising New Treatments, S.F. CHRON., May 8, 2007, at C1 (stating
that insurance companies balk at covering the full price of biologic therapies
because they are too expensive).
140. Patton, supra note 32 (“From 1998 to 2006, the costs of [biologic
drugs] shot up 505 percent . . . .”).
141. Karen Tumulty & Michael Scherer, You Don’t Know Him (He’s a
Lobbyist) but He May Be the Biggest Winner in Health-Care Reform. So Who
Loses?, TIME, Nov. 2, 2009, at 38, available at http://www.time.com/
time/magazine/article/0,9171,1931729,00.html.
142. Patton, supra note 32.
143. Tumulty & Scherer, supra note 141, at 38.
144. Id.
145. Alfred B. Engelberg et al., Balancing Innovation, Access, and Profits—
Market Exclusivity for Biologics, 361 NEW ENG. J. MED. 1917, 1917 (2009);
Andrew Pollack, Cutting Dosage of Costly Drug Spurs a Debate, N.Y. TIMES,
Mar. 16, 2008, at 1, available at http://www.nytimes.com/2008/03/16/business/
16gaucher.html?pagewanted=all&_r.
146. Patton, supra note 32.
147. Roth, supra note 29, at 6.
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competition.148 However, the ABLA faces distinct challenges
that may hinder the purpose to promote accessibility. Part II.B
explores four aspects of these challenges: complexity and
delicacy of biologics, statutory and administrative ambiguity,
excessively long FDA exclusivity, and evergreening.
1. The Complexity and Delicacy of Biologics
Many commentators opine that it is scientifically
impossible to produce a bioequivalent generic biologic, as in
generic small-molecule drugs, due to the natural complexity
and delicacy of biologics.149 Biologic products are extremely
sensitive to environmental conditions.150 Any minor change in
the manufacturing process, such as temperature, water quality,
or even external packaging, can change the overall safety and
efficacy of biologics.151
The story of Eprex highlights the extreme delicacy of
biologics and the difficulties in making FOBs.152 Eprex, made
by Janssen-Cilag,153 is an FOB of Epogen, made by Amgen.154
Eprex, like Epogen, treats chronic kidney disease patients for
aplasia.155 In 1998, incidence of pure red-cell aplasia, a rare
disorder that manifests as a severe, sudden-onset anemia with
complete absence of red blood cell precursors in the bone
marrow, were noticed among the patients receiving Eprex.156
The uncommon scenario was that the incidents happened in
patients receiving Eprex in Europe, but not in the United

148. Tzeng, supra note 68, at 135.
149. E.g., Park et al., supra note 79, at 1688–89. Many scientists believe
that it is impossible to produce a generic biologic that is bioequivalent and
bioavailable as the referenced biologic. This is the reason why the scientific
communities use the term “follow-on biologics” instead of “generic biologics.”
See Huub Schellekens, Biosimilar Epoetins: How Similar Are They?, 3 EUR. J.
HOSP. PHARMACISTS 43, 43–44 (2004).
150. Park et al., supra note 79, at 1689.
151. Id.; see also JUDITH A. JOHNSON, CONG. RESEARCH SERV., FDA
REGULATION OF FOLLOW-ON BIOLOGICS, at i (2010) (“Biologics often require
special handling (such as refrigeration) and are usually administered to
patients via injection or infused directly into the bloodstream.”).
152. Katia Boven et al., The Increased Incidence of Pure Red Cell Aplasia
with an Eprex Formulation in Uncoated Rubber Stopper Syringes, 67 KIDNEY
INT’L 2346, 2346 (2005).
153. Id.
154. See EPOGEN, http://www.epogen.com (last visited Sept. 16, 2013)
(directing the homepage to Amgen).
155. Boven et al., supra note 152, at 2346.
156. Id.
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States.157 The reason turned out to be that the medical
facilities in Europe administered Eprex using syringes with
uncoated rubber stoppers instead of coated ones.158 The
uncoated rubber stopper releases certain organic compounds
that cause coagulation of the active proteins that induce
increased immunogenicity.159 The whole incident highlights the
natural delicacy of biologics, showing that even a minor change
in the delivery equipment (e.g., rubber stopper), could be
lethal.160 Commentators argue that this natural delicacy of
biologics potentially renders the interchangeability of the
FOB—the idea that the FOB can be substituted by a
pharmacist
without
consulting
medical
doctors—
impracticable.161
2. Statutory and Administrative Ambiguity
The BPCIA has been enacted, but the statutory
interpretation and administrative implementation are far from
definite.162 Particularly, whether the twelve-year FDA
exclusivity is a data or market exclusivity is still under
debate.163 The provision of “exclusivity for reference product” of
the BPCIA states:
(A) Effective date of biosimilar application approval
Approval of an application [i.e., ABLA] under this subsection may
not be made effective by the Secretary until the date that is 12 years
after the date on which the reference product was first licensed
under subsection (a).
(B) Filing period

157. Id.
158. Id. at 2346–47.
159. See id. at 2352 (“[T]he evidence of [syringes with uncoated rubber
stoppers’] capacity to increase the immunogenicity in experimental animals [ ]
suggest[s] that [the organic compounds] were the critical contributory factor in
the increased incidence of antibody mediated PRCA attributed to Eprex.”).
160. Id. at 2346–47.
161. E.g., Jonathan Stroud, The Illusion of Interchangeability: The Benefits
and Dangers of Guidance-Plus Rulemaking in the FDA’s Biosimilar Approval
Process, 63 ADMIN. L. REV. 599, 618 (2011). As of the time this Note was
written, the FDA had not approved any FOB through ABLA.
162. Brian R. Dorn, Biosimilars Law in Limbo: An Update on Biosimilars
and Politics, http://www.iptoday.com/issues/2012/02/biosimilars-law-in-limboupdate-biosimilars-and-politics.asp (last visited Sept. 9, 2013).
163. Id.
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An application under this subsection may not be submitted to the
Secretary until the date that is 4 years after the date on which the
reference product was first licensed under subsection (a).164

The four-year exclusivity in (B) is generally interpreted to
be data exclusivity because the statutory language matches the
definition of data exclusivity (i.e., the FDA will not accept any
filing of an ABLA until four years after the reference biologic is
approved because FOB manufacturers are precluded from
relying on innovator data).165 The debate focuses on whether
the twelve-year exclusivity provided in (A) is market or data
exclusivity.166
The FDA, on October 5, 2010, interpreted the twelve-year
exclusivity in (A) as a market exclusivity.167 This is a
reasonable interpretation for two reasons. First, the statutory
language is: “Approval of an application under this subsection
may not be made effective . . . until the date that is 12 years
after the date on which the reference product was first
licensed” matches the general understanding of market
exclusivity (i.e., the FDA can accept and review an ABLA but
will not approve it until the twelve-year market exclusivity
expires).168 Second, reading (A) as data exclusivity renders (B)
superfluous.169 However, Senators Hagan, Hatch, Enzi, and
Kerry,170 and Representatives Eshoo, Inslee, and Barton171

164. Biologics Price Competition and Innovation Act of 2009, Pub. L. No.
111-148, sec. 7002, § 262, 124 Stat. 119, 807 (2010).
165. Cf. 21 U.S.C. § 355(c)(3)(E)(ii) (2012).
166. Emily K. Strunk, Debate Over Exclusivity in Biologics Provision of
PPACA Heats Up, AKIN GUMP HEALTH REFORM RESOURCE CENTER (Feb. 14,
2011),
http://aghealthreform.com/2011/02/14/debate-over-exclusivity-inbiologics-provision-of-ppaca-heats-up.
167. Notice of Public Hearing, 75 Fed. Reg. 61,498 (Oct. 5, 2010) (“The
BPCI Act also includes, among other provisions: A 12-year period of marketing
exclusivity from the date of first licensure of the reference product . . . .”).
168. Karst, supra note 49.
169. If (A) were a data exclusivity period then (B) would be superfluous,
because a twelve-year period certainly covers a four-year period. In other
words, if (A) is a data exclusivity period then (B) has no effect.
170. Letter from Senators Kay R. Hagan, Orrin Hatch, Michael Enzi, and
John F. Kerry, U.S. Senate, to Dr. Margaret Hamburg, Comm’r of Food and
Drug Admin. (Jan. 7, 2011) [hereinafter Letter from Senators], available at
http://www.hpm.com/pdf/1-7-11%20Senate%20Biologics%20letter%20to%
20FDA.pdf (clarifying that the BPCIA does not provide market exclusivity, but
provides data exclusivity); see also Dorn, supra note 162.
171. Letter from Representatives Anna G. Eshoo, Jay Inslee, and Joe
Barton, U.S. House of Representatives, to Dr. Margaret Hamburg, Comm’r of
Food & Drug Admin. (Dec. 21, 2010), available at http://www.hpm.com/
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responded to the FDA’s interpretation, clarifying that
§ 262(k)(7)(A) is a data exclusivity.
The difference between data or market exclusivity is
significant; it means three to four years of delay in introducing
FOB competition and tens of billions of dollars to the general
public.172 The delay is the time for conducting clinical trials and
FDA regulatory reviews.173 According to FDA guidance
documents, ABLA applicants will generally be required to
conduct a certain scale of clinical trials to show biosimilarity or
interchangeability.174 After the clinical trials are completed, the
regulatory review phase for the FDA to approve a biologic takes
about sixteen months.175 In the case that the twelve-year
exclusivity is data exclusivity, an FOB manufacturer will have

pdf/EIB%20Ltr%20FDA%20DEC%202010.pdf (clarifying the twelve-year
exclusivity is a data exclusivity); see Dorn, supra note 162.
172. For reasons why ABLA is expected to take, on average, three to four
years (including clinical trial phase and regulatory review phase) to be
approved, see Trends in NDA and BLA Submissions and Approval Times,
FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/ReportsManualsForms/
Reports/UserFeeReports/PerformanceReports/PDUFA/ucm209349.htm
(last
updated May 4, 2010).
173. Clinical trial and regulatory review are two different time periods. An
innovator drug company submits an investigational new drug (IND)
application to conduct the clinical trials. After the clinical trials are completed,
the innovator company then submits a new drug application (NDA) to start
the formal regulatory review process. See Running Clinical Trials, FOOD &
DRUG
ADMIN.,
http://www.fda.gov/ScienceResearch/SpecialTopics/
RunningClinicalTrials/ucm155713.htm (last updated Mar. 20, 2013) (listing
the regulations governing clinical trials and regulatory reviews).
174. FDA, BIOSIMILARS: QUESTIONS AND ANSWERS REGARDING
IMPLEMENTATION OF THE BIOLOGICS PRICE COMPETITION AND INNOVATION
ACT OF 2009, at 8–12 (2012) [hereinafter BIOSIMILARS: QUESTIONS AND
ANSWERS],
available
at
http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf
(noting that to demonstrate biosimilarity, an ABLA applicant has to conduct
rigorous structural and functional comparisons showing minimal or no
difference between the FOB and the referenced biologic (e.g., bench/lab tests);
then, the ABLA applicant should produce comparative human clinical trial
data showing human pharmaceutical kinetic (PK), pharmaceutical dynamic
(PD), and immunogenicity studies in an “appropriate population”). This shows
that the FDA will certainly require a level of clinical trials appropriate to the
biologic. See also Makiko Kitamura & David Wainer, Biosimilars Lure Major
Drugmakers into the Generics Biz, BLOOMBERG BUSINESSWEEK (Mar. 21,
2013),
http://www.businessweek.com/articles/2013-03-21/biosimilars-luremajor-drugmakers-into-the-generics-biz (noting FOB companies might have to
do even more clinical trials than those required by the FDA to convince
skeptical medical practitioners to use their FOBs—“life-and-death drugs”).
175. Grabowski, supra note 63, at 481 (showing in Figure 1 that the
regulatory review period for biologics takes an average of sixteen months).
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to submit an ABLA after twelve years and take another three
to four years to go through the clinical trials and regulatory
review process.176 This de facto extends the monopoly period
enjoyed by the innovator biologic manufacturers beyond twelve
years. Whereas, if (A) were market exclusivity and (B) were
data exclusivity, an ABLA could be submitted four years after
the reference biologic was approved, and it could likely go
through clinical trials and regulatory reviews before the
twelve-year data exclusivity expired.177 Consequently, the FOB
could be on the market the very day the twelve-year market
exclusivity expires.
Besides statutory ambiguity, the FDA regulations to
implement the ABLA are also not clear. The FDA has ten years
from the enactment of the BPCIA to finalize the regulatory
structure of abbreviated biological license application, meaning
the implementation standards are unlikely to be finalized until
2020.178 On February 9, 2012, the FDA released three draft
guidance documents that shed some light on the
implementation of ABLA: (1) Scientific Considerations in
Demonstrating Biosimilarity to a Reference Product;179 (2)
Quality Considerations in Demonstrating Biosimilarity to a
Reference Protein Product: Biosimilars;180 and (3) Biosimilars:
Questions and Answers Regarding Implementation of the
Biologics Price Competition and Innovation Act of 2009.181 The
documents highlight that, in approving an FOB, the FDA will
make a case-by-case determination, examining the totality of
the evidence.182 In view of the natural delicacy and complexity
176. See Karst, supra note 49 (stating that generic supporters argue that
interpreting the twelve-year FDA exclusivity as a data exclusivity, which
prevents biosimilar (i.e., ABLA) submissions, has serious consequences and
that consumers will have to endure an indeterminate delay of FDA review and
approval that could extend “far beyond the 12-year total that was set in the
legislation”).
177. Cf. Bagley, supra note 48, at 15–18 (explaining market exclusivity
within the context of pediatric testing exclusivity and orphan drug
exclusivity).
178. Stroud, supra note 161, at 620.
179. SCIENTIFIC CONSIDERATIONS, supra note 77.
180. FDA, QUALITY CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY
TO A REFERENCE PROTEIN PRODUCT: BIOSIMILARS (2012) [hereinafter QUALITY
CONSIDERATIONS],
available
at
http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
181. BIOSIMILARS: QUESTIONS AND ANSWERS, supra note 174.
182. SCIENTIFIC CONSIDERATIONS, supra note 77, at 2; see also Steven
Kozlowski et al., Developing the Nation’s Biosimilars Program, 365 NEW ENG.
J. MED. 385, 386 (2011).
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of biologics, additional animal and clinical studies will
generally be required.183 However, the scope and extent of such
studies can be reduced if more extensive, fingerprint-like
analyses are provided.184 Immunogenicity is considered a
critical risk factor in assessing biosimilarity.185 The FDA is
aware that pharmaceutical companies often make changes to
the manufacturing process.186 The FDA will continuously
monitor the quality of FOBs in regard to those changes.187 A
biologic will be considered interchangeable with a reference
product if the developer demonstrates similar clinical results in
all types of patients, and the risk associated with switching
between the two biologics is not greater than continuously
using the reference biologic.188
3. Excessively Long FDA Exclusivity
The history of the Hatch-Waxman Act shows that the
patent-invalidation challenge is an important mechanism to
increase drug price competition.189 However, the twelve-year
FDA exclusivity in the BPCIA, regardless of whether it is a
data or market exclusivity, arguably vacates the incentives to
challenge biological patents.190 This is because FDA exclusivity
183. SCIENTIFIC CONSIDERATIONS, supra note 77, at 10–19.
184. Id. at 7.
185. Id. at 7–10.
186. See QUALITY CONSIDERATIONS, supra note 180, at 3 (“Since 1996, FDA
has approved many manufacturing process changes for licensed biological
products, based on a demonstration of product comparability before and after
the process change, as supported by quality criteria and analytical testing and
without the need for additional nonclinical data and clinical safety and/or
efficacy studies.”).
187. Id. at 4 (stating that if the reference product and the proposed protein
product cannot be adequately characterized, the FDA recommends that the
sponsor consult the FDA for guidance).
188. Id. at 4.
189. See Higgins & Graham, supra note 91, at 370 (noting patent invalidity
challenges brought by generic companies cut down brand-name companies’
profit significantly).
190. See Engelberg et al., supra note 145, at 1917 (noting that the
Biosimilar Act guarantees innovator drug companies twelve years of market
exclusivity for a new biologic agent before any biosimilar product could be
approved, even in the absence of a valid patent); see also Tzeng, supra note 68,
at 156 (stating that the twelve-year data exclusivity runs potentially longer
than patent protection and demonstrating that this twelve-year exclusivity
destroys the incentives for generic drug companies to bring patent-invalidity
challenges because even if the underlying patents are invalidated, the FOB
still has to wait for the twelve-year FDA exclusivity to expire to hit the
market). In addition, because this twelve-year period is likely to last longer
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remains effective even if the patents covering the reference
biologics are invalidated and a twelve-year period after FDA
approval is likely to run longer than the underlying patents.191
This twelve-year FDA exclusivity is likely to live longer
than the remaining active patent term.192 Active patent term
refers to the overall patent life minus the overall
administration time spent in the United States Patent and
Trademark Office (USPTO) and the FDA.193 The overall patent
life is the summation of twenty years from filing, the patent
term adjustment (PTA) granted by the USPTO, and the patent
term extension (PTE) granted by the FDA.194 Put simply, PTA
is granted if USPTO examination took more than three years
from filing to issuance.195 The examination time in excess of
three years will be granted as PTA.196 On average, the USPTO
takes 33.7 months to review a patent application, slightly short
of three years.197 Thus, PTA is likely to be zero. The period of
PTE granted by the FDA is calculated by adding one-half of the
time during which the drug is evaluated as an “investigational
new drug” to the time the drug is pending approval at the
FDA.198 However, the extension cannot exceed a maximum

than the remaining patent life, there is no point for generic drug companies to
spend the litigation resources to invalidate the underlying patents.
191. Engelberg et al., supra note 145, at 1917.
192. See Tzeng, supra note 68, at 156 (stating that the twleve-year data
exclusivity runs potentially longer than patent protection). I use the term
“active patent term” to mean the patent period that the drug is actually on the
market and generating revenue for the patentee. This active patent term is
the overall patent life minus overall administration time. Overall patent life
means the regular twenty years from filing, plus patent term adjustment, plus
patent term extension. Overall administration time is the time spent in the
U.S. Patent and Trademark Office to secure the patent and the FDA to get the
drug approved.
193. Id.
194. Id.
195. 35 U.S.C. § 154(b) (2006 & Supp. V 2011) (guaranteeing prompt
patent and trademark office responses and specifying the conditions of
granting patent term adjustments); see also Bagley, supra note 48, at 11
(“[T]he USPTO is expected to take no more than three years to examine and
issue a patent on an application. If the USPTO fails to issue a patent within
three years from the actual U.S. filing date, it must extend the term of the
resulting patent one day for each day beyond the three-year period until the
patent issues.”).
196. See Bagley, supra note 48, at 11.
197. Jim Singer, How Long Does Patent and Trademark Prosecution Take?,
IP SPOTLIGHT (Dec. 14, 2011), http://ipspotlight.com/2011/12/14/1780/.
198. 35 U.S.C. § 156(c)(2) (2006 & Supp. V 2011).
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period of five years,199 nor can it extend patent expiration to a
date more than fourteen years after being approved by the
FDA.200 The average PTE awarded by the FDA in approving a
new drug is 43.2 months.201 The FDA takes an average of 110
months to approve an innovator biologic, counting both the
clinical phase and the regulatory review phase.202
Thus, the average active patent term for a new biologic is
(in months): 240 (20 years from filing) + 0 (patent term
adjustment) + 43.2 (PTE) – 33.7 (PTO examination time) – 110
(FDA approval time) = 139.5 months (11.65 years). Therefore, it
is more likely than not that the patents covering innovator
biologics will expire before the twelve-year FDA exclusivity
expires.203
In light of all the characteristics of this twelve-year FDA
exclusivity (independent from and likely to last longer than the
underlying patents), there is little to no incentive for FOB
companies to challenge the patents.204 President Obama
expressed his concern that the twelve-year FDA exclusivity tips
the balance toward innovator drug companies and proposed to
reduce it to seven years.205 Commentators even speculate that,

199. § 156(g)(6)(A).
200. § 156(c)(3).
201. Charles Clift, The Value of Patent Term Extensions to the
Pharmaceutical Industry in the USA, 5 J. GENERIC MED. 201, 205 (2008)
(showing that the average PTE awarded to the forty best selling drugs in 2006
was 43.2 months).
202. See Grabowski, supra note 63, at 481–82 (showing that, on average,
standard NCE/BLA applications take 110 months to be approved). An
innovator biologic (i.e., BLA) takes on average 110 months to be approved,
including both the time of clinical trial and regulatory review.
203. See Tzeng, supra note 68, at 156.
204. See Engelberg et al., supra note 145, at 1919 (noting that a rigid
twelve-year exclusivity period essentially eliminates the need for innovator
companies to defend any patents).
205. See Mike Palmedo, Obama’s Deficit Plan Would Reduce Data
Exclusivity for Biologics and Ban Pay-for-Delay Patent Settlements,
INFOJUSTICE.ORG (Sept. 20, 2011), http://infojustice.org/archives/5585 (“[The
Obama administration’s] proposal would reduce data exclusivity for biologic
medicines to 7 years . . . and would ‘prohibit additional periods of exclusivity
for brand biologics due [to] minor changes in product formulations, a practice
often referred to as “evergreening.”’ The administration predicts that the
shorter periods of data exclusivity will ‘encourage faster development of
generic biologics while retaining appropriate incentives for research and
development for the innovation of breakthrough products.’”); see also Dorn,
supra note 162; Andrew Pollack, Obama Pushes More Competition on Biologic
TIMES,
Sept.
19,
2011,
available
at
Drugs,
N.Y.
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in view of this excessively long twelve-year exclusivity, the
ABLA pathway will not be used much because FOB companies
will likely ignore ABLAs and file regular Biologics License
Applications (BLAs), thus avoiding the delay of the twelve-year
period.206 This creates a lose-lose-lose situation for the FOB
companies, the innovator companies, and the general public,
because FOB companies will not be able to save cost by relying
on innovators’ clinical data, nor will the innovator drug
company get to enjoy the full twelve-year exclusivity, nor will
the general public enjoy the drug price competition.207
4. Evergreening
Evergreening strategy refers to patenting activities by
innovator drug companies on ancillary aspects of the drugs.208
The natural complexity of biologics provides convenient
mechanisms for innovator drug companies to engage in
evergreening, such as reformulation of drugs, new
manufacturing processes, or quality-control methodologies.209
http://prescriptions.blogs.nytimes.com/2011/09/19/obama-pushes-morecompetition-on-biologic-drugs.
206. See Engelberg et al., supra note 145, at 1918 (“[M]anufacturers of
potential follow-on products would probably prefer to ignore the new pathway
and opt to file a standard BLA, which would not be subject to the 12-year
delay. Any higher cost would be offset by the greater profit opportunity
available to early market entrants. Therefore, as currently fashioned, the
biosimilar legislation would have no value, because it would create a pathway
that would scarcely be used. Innovators would not get the benefit of the
exclusivity provision, and the public would not get the benefit of the enhanced
price competition that would result from increasing the number of
competitors.”).
207. Id. Engelberg speculates that the twelve-year FDA exclusivity creates
a lose-lose-lose situation among the innovator company, FOB company, and
the general public. Innovator companies will not enjoy the twelve-year
exclusivity because FOB companies will design around and go through regular
BLA to avoid the delay of the twelve-year period. FOB companies will not be
able to enjoy the cost-saving, fast track ABLA because regular BLA is
preferred. The general public will not be able to enjoy low price biologics
because FOB companies will have to price higher in order to recoup the
investment for going through regular BLA.
208. See Hemphill & Sampat, supra note 66, at 327–28 (describing
evergreening as securing or acquiring patents on ancillary aspects with
doubtful validity in order to delay generic competition).
209. See Christopher Weaver et al., Biotech Drugs Still Won’t Copy, WALL
ST. J., Feb. 27, 2013, at B1 (noting that innovator biologic companies can gain
patents on manufacturing procedures and formulations to extend the market
monopoly period). The CEO of AbbVie Inc., a spin-off of Abbott Laboratories,
said that AbbVie has more than 200 such patents on Humira, an innovator
biologic treating arthritis. Id.
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For example, an innovator biologic company can secure a
patent on a reformulation of a biologic, improving certain
peripheral effects.210 Then, right before the expiration of the
twelve-year exclusivity, the innovator drug company can obtain
a quick approval of the reformulated biologic by referring to its
own clinical data and enjoy a renewed twelve-year monopoly.211
The evergreening issue was debated in Congress.212
Senator Orrin Hatch and Senator Kay Hagan sent a letter on
January 7, 2011 calling on the FDA to interpret the BPCIA
such that innovator drug companies should get a renewed
twelve years of exclusivity if manufacturers alter an existing
product to improve safety or potency.213 Senator Sherrod Brown
and proponents of generic companies disagreed with this
interpretation and showed great concerns that this tweak-torenew tactic would increase costs for consumers, businesses,
and taxpayers.214 President Obama also expressed his intention
to prohibit evergreening.215 Siding with the President, Pamela
Jones Harbour, the then Commissioner of the FTC, expressed
her opinion in June of 2009: “no additional period of branded
exclusivity is needed to spur the development of new drug
products” because pioneer biologics are already covered by
varied patents and market-based exclusivities, providing
strong incentives to innovate.216
210. See Alicia Mundy, Biotech Firms Fight Generics, WALL ST. J., Jan. 12,
2011, http://online.wsj.com/article/SB1000142405274870388920457607825226
0327210.html (noting that Senators Hatch and Hagan stated in a letter to the
FDA that companies should get an additional twelve years of exclusivity if an
existing product is altered to improve safety or potency).
211. Id. Note that the twelve-year exclusivity excludes follow-on
competitors but not the original data owner.
212. Id.
213. Letter from Senators, supra note 170 (“If a manufacturer modifies an
approved product to produce a change in safety, purity or potency, the
modified product is rightly considered a new product. It will be protected by
the data exclusivity provisions afforded new products. Exclusivity on the first
generation product will expire as scheduled.”).
214. See Mundy, supra note 210.
215. See Palmedo, supra note 205 (noting that the Obama administration
proposes to prohibit additional periods of exclusivity for brand biologics due to
minor changes in product formulations, a practice often referred to as
“evergreening”).
216. See Pamela Jones Harbour, Comm’r, FTC, Oral Statement Before the
Subcommittee on Health, Committee on Energy and Commerce, United States
House of Representatives, Emerging Health Care Issues: Follow-on Biologic
Drug
Competition
(June
11,
2009),
available
at
http://democrats.energycommerce.house.gov/Press_111/20090611/testimony_
harbour.pdf.
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A recent case in 2012, Momenta Pharmaceuticals, Inc. v.
Amphastar Pharmaceuticals, Inc., provides an example of
evergreening in therapies that require a high level of quality
control, such as biologics.217 Momenta Pharmaceuticals
(Momenta) and Amphastar Pharmaceuticals (Amphastar) are
both generic drug companies making generic versions of
Lovenox (enoxaparin), produced by Aventis Pharmaceuticals.218
Enoxaparin requires a high level of continuous quality
control.219 In order to ensure quality, the FDA required both
Momenta and Amphastar to profile their products via mass
spectroscopy, nuclear magnetic resonance spectroscopy,
modifying reagents, or modifying enzymes, to show their
enoxaparin is equivalent to Lovenox.220 Amphastar was the
first to be approved by the FDA.221 However, Momenta owns a
method patent (Patent No. 7,575,886, “the ‘866 patent”) in
quality control (i.e., an evergreening patent) to show its product
is equivalent to Lovenox.222 Before Amphastar’s enoxaparin
could reach the market, Momenta asserted infringement
actions alleging that Amphastar inevitably infringed its ‘866
patent.223 Amphastar’s enoxaparin eventually reached the
market after Momenta.224 This scenario highlights an
evergreening strategy: a quality-control patent can
conveniently be used to extend a market monopoly in therapies

217. Momenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348,
1349–52 (Fed. Cir. 2012).
218. Id.
219. Id. at 1349–50.
220. Id. at 1350–51.
221. Id. at 1351.
222. Id.
223. Id.
224. Id. at 1351–62. The majority ruled against Momenta in Momenta v.
Amphastar. Judges Moore and Dyk reasoned that even if Amphastar infringed
Momenta’s profiling method, patent ‘866, it was exempted under the safe
harbor (35 U.S.C. § 271(e)(1)) because the quality control and profiling of the
product falls within the statutory language: “reasonably related to the
development and submission of information under a Federal law which
regulates the manufacture, use or sale of drugs . . . .” Id. at 1357–59. The
majority ruling partially answers the concern of using quality-control and
product-profiling patents to extend market monopoly. However, Judge Rader
dissented, arguing that the safe harbor should be limited to pre-approval
activities. Id. at 1361–76 (Rader, J., dissenting). If Judge Rader’s point of view
subsequently prevails, the activities of continuous quality-controlling and
profiling after an FOB is approved will constitute patent infringement. In
other words, brand-name companies can assert quality control method patents
to deter FOBs.
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that require continuous, high-quality monitoring, such as
biologics.225
C. BIOSIMILAR—A GAME OF BRAND-NAME COMPANIES
Maybe the wrestling between the proponents for
innovators and FOB companies will eventually be moot because
the biosimilar game is likely among brand-name companies.226
In 2009, the FTC stated the following in one report:
FOB products are likely to take eight to ten years to develop, and
their development will likely cost between $100 and $200 million.
These amounts differ substantially from the product development
costs for small-molecule generic drugs, which typically take three to
five years to develop and cost between $1 and $5 million.227

In light of the high cost to enter the market, the dynamics
of biosimilar competition will likely be “brand-name to brandname,” rather than “brand-name to generic” competition.228
Indeed, Merck and Pfizer, both recognized as brand-name
companies, have started to develop FOBs referencing Amgen
and Roche’s biologic products.229

225. See Weaver et al., supra note 209 (stating that Merck retreated from a
plan to develop an FOB of Enbrel, an innovator biologic made by Amgen,
because Amgen recently gained a new patent on Enbrel).
226. See Kitamura & Wainer, supra note 174 (noting it would take about
$100 to $200 million to develop an FOB, much higher than the $50 million
needed to make a generic small-molecule drug). The higher threshold makes
biosimilar development likely to be a game among big pharmaceutical
companies. Id.
227. FTC, EMERGING HEALTH CARE ISSUES: FOLLOW-ON BIOLOGIC DRUG
COMPETITION 6 (2009) [hereinafter EMERGING HEALTH CARE ISSUES],
available at http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf. The
report highlights that biosimilars are a game for deep pockets. The medium or
small generic firms are not likely to have sufficient capital and equipment to
participate in the competition. Therefore, biosimilar development is likely to
be a war among brand-name companies.
228. See Linda A. Johnson, Merck, Samsung JV Team Up on Biosimilar
BUSINESSWEEK
(Feb.
20,
2013),
Medicines,
BLOOMBERG
http://www.businessweek.com/ap/2013-02-20/merck-samsung-jv-team-up-onbiosimilar-medicines (noting that Merck, a brand-name drug company,
collaborated with Samsung in a joint venture to develop biosimilars).
229. See Peter Loftus, Merck Teams Up with Parexel on Biosimilars, WALL
ST. J., Jan. 12, 2011, http://online.wsj.com/article/SB100014240527
48704803604576078160079036994.html (noting that Merck, Pfizer, and some
other big brand-name drug makers view biosimilars as a big market
opportunity and aim to participate as FOB companies); see also Pfizer
Carrying out Biosimilar Trastuzumab Trial in US, GENERICS & BIOSIMILARS
INITIATIVE (Oct 19, 2012), http://www.gabionline.net/Biosimilars/Research/
Pfizer-carrying-out-biosimilar-trastuzumab-trial-in-US. Pfizer is carrying out
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D. STRIKING A BETTER BALANCE: A SIX-YEAR DATA EXCLUSIVITY
AND A DYNAMIC SIX-TO-TWELVE-YEAR MARKET EXCLUSIVITY
A rigid, twelve-year FDA exclusivity, regardless of whether
it is data or market exclusivity, is too long and tips the scale in
favor of innovator companies. As articulated previously, a
twelve-year exclusivity period is likely to out-live the
underlying patents in the majority of the cases and eliminates
the incentives to challenge these patents.230 This works against
the public interest of promoting drug accessibility, especially in
view of the high market entrance barrier and evergreening
tactics in biologic therapies.231 However, reducing the FDA
exclusivity straight to a rigid seven-year time frame, as
President Obama suggested, might tip the scale too favorably
toward the FOB companies’ side.232 In striking a better
balance, this Note suggests a regulatory scheme of a six-year
data exclusivity and a six-to-twelve-year dynamic market
exclusivity. The dynamic market exclusivity would be
adjudicated by a panel of experts from both the FTC and the
FDA at the end of the six-year period.
Under this scheme, innovator companies have six years of
absolute market monopoly covered by patent exclusivity, data
exclusivity, and market exclusivities.233 During this period,
an FOB referencing Trastuzumab, a biologic made by Roche to treat breast
cancer; Trastuzumab is Roche’s third-best-selling drug. Id.
230. See supra Part II.B. In a nutshell, Part II.B. argues that (1) in view of
the natural delicacy of biologics, it is difficult to produce biosimilars; to enter
the biologics market requires large capital and advanced technologies
compared to entering the market of small-molecule drugs; (2) a twelve-year
exclusivity period is likely to out-live the underlying patents in the majority of
the cases and eliminates the incentives to challenge the patents; and (3) a
twelve-year period is likely to aggregate the negative impacts of evergreening
tactics on drug-price competition, especially if the FDA adopted the tweak-torenew policy.
231. See supra Part II.B.
232. See Palmedo, supra note 205. President Obama and proponents of
generic drug companies supported a seven-year exclusivity. This Note’s
Author believes a rigid seven-year period is too short and is not sufficient for
innovator companies to recoup their investments. The reasons that justify
innovator companies having FDA exclusivity longer than seven years are
articulated in Part II.A of this Note: (1) it costs a lot more to develop a biologic
therapy then a small-molecule drug; (2) biotechnology patents are particularly
vulnerable to being challenged; and (3) innovation decreases steadily under
the Hatch-Waxman incentive system.
233. See generally Bagley, supra note 48. During the first six years, an
innovator company would have all three kinds of market exclusivities: patent
exclusivity, data exclusivity, and market exclusivity. Patent exclusivity
prevents FOB companies from using, selling, or importing the protected
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innovator companies will face no competition, even if the
underlying patents are invalidated.234 At the end of the six-year
period, the FTC and the FDA will assemble an expert panel to
adjudicate how many more years of market exclusivity will be
granted.235 In the adjudication process, there should be trialtype procedures allowing the innovator companies to submit
briefs, present experts, answer questions, and orally advocate
their positions.236 The benefit of having this adjudication at the
end of the six-year period is that it allows the FTC and the
FDA to evaluate the sales profile of the biologic during that
first five to six years.237 This sales information is extremely
helpful in evaluating how many more years of market
exclusivity should be granted to allow innovator companies to
recoup their investments.238
Some commentators might argue that this individualized
adjudication is inefficient and will consume heavy
administrative resources. This Note disagrees. According to the
FDA, the number of approved BLAs was four in 2008, seven in
2009, six in 2010, and six in 2011.239 Since the annual number
biologic. Data exclusivity prevents FOB companies from submitting an ABLA.
Market exclusivity prevents the FDA from approving an ABLA. The
overlapping protection of all three exclusivity powers provides innovator
companies with absolute market monopoly power.
234. See Tzeng, supra note 68, at 156 (explaining that FDA exclusivity is
independent from patent exclusivity).
235. See generally EMERGING HEALTH CARE ISSUES, supra note 227. The
FTC has the expertise in balancing customer protection and market monopoly
(e.g., antitrust enforcement). The FDA has the expertise in assessing the
technology and clinical effects of the biologic. Thus, an expert panel from both
the FTC and the FDA will be ideal in adjudicating the market exclusivity.
236. See 5 U.S.C. §§ 554–557 (2012). Administrative formal/informal
adjudication processes specified in this code might shed some light on this
market exclusivity adjudication process.
237. See Grabowski, supra note 63, at 485 (demonstrating that mean sales
of a biologic therapy grow almost linearly from the first year, at $128 million
per year, to the ninth year, peaking at $713 million per year; the sales slightly
decrease after the ninth year but remain above $600 million through the
fourteenth year). Thus, having the first five to six years of sales data helps the
expert panels from the FTC and the FDA to accurately predict how many
more years an innovator company will need to recoup its investment.
238. Id.
239. See FDA, CDER DRUG AND BIOLOGIC APPROVALS FOR CALENDAR
YEAR
2008,
available
at
http://www.fda.gov/downloads/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Drugand
BiologicApprovalReports/UCM200924.pdf; FDA, CDER DRUG AND BIOLOGIC
APPROVALS FOR CALENDAR YEAR 2009, available at http://www.fda.gov/
downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandA
pproved/DrugandBiologicApprovalReports/PriorityNDAandBLAApprovals/UC
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of approved BLAs constantly remains single digit, adjudication
for each BLA will not impose undue burden on the
administrative system.
In promoting innovation, this suggested scheme recognizes
the heavy up-front investment in developing a new biologic
therapy and provides mechanisms to adjudicate individualized
market exclusivity for innovator companies to recoup their
investments.240 The innovator companies may present evidence
showing how much money they have spent on bringing the
biologic to the market and argue for how many more years they
need to recoup the investments. In promoting accessibility, this
suggested scheme avoids the potential extension of market
monopoly due to FOB companies’ inability to complete the
ABLA approval process before the expiration of innovators’
market exclusivity.241 This is because FOB companies can
submit ABLAs at the end of the six-year period (i.e., the
expiration of the data exclusivity, under this scheme) and use
the expected three to four years of ABLA approval process to
finish the required clinical trials and regulatory review.242 The
M090995.pdf; FDA, CDER DRUG AND BIOLOGIC APPROVALS FOR CALENDAR
YEAR
2010,
available
at
http://www.fda.gov/downloads/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Drugand
BiologicApprovalReports/UCM260585.pdf; FDA, CDER DRUG AND BIOLOGIC
APPROVALS FOR CALENDAR YEAR 2011, available at http://www.fda.gov/
downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandA
pproved/DrugandBiologicApprovalReports/UCM276984.pdf.
240. See Grabowski, supra note 63, at 489.
241. See supra Part II.B.2. If the twelve-year FDA exclusivity is explained
as a data exclusivity, ABLA applicants can submit applications only after the
expiration of the twelve-year data exclusivity and take another three to four
years to finish the FDA approval process. This de facto extends innovators’
market monopoly period.
242. Trends in NDA and BLA Submissions and Approval Times, supra
note 172. Since no ABLA has been approved by the FDA yet, no one knows
how long it would take for an FOB to be approved by the FDA. But we can do
some guess-work from the empirical data of innovator biologics and generic
small-molecule drugs. The average approval time for innovator biologics (i.e.,
BLAs) should be the upper limit for an ABLA because the ABLA refers to a
BLA’s clinical data. This means a much smaller scale of clinical trials and that
it should take a shorter time to be approved than a BLA. On the other hand,
the average approval time for generic small-molecule drugs (i.e., ANDA)
should establish the lower limit for ABLA, because biologics normally take
longer to be approved than small-molecule drugs. See Grabowski, supra note
63, at 482. An innovator biologic (i.e., BLA) takes on average 110 months to be
approved, including both the time for clinical trials and regulatory review. See
Kurt R. Karst, OGD’s ANDA Backlog and Median ANDA Approval Times Are
Up—WAY UP! “The Solution Lies in Resources,” Says FDA Commissioner
Hamburg, FDA L. BLOG (Feb. 25, 2010), http://www.fdalawblog.net/

2014] BIOLOGICS: INNOVATION AND ACCESSIBILITY

649

ABLA approval process will likely conclude before, or at least
not long after, the expiration of the referenced biologic’s market
exclusivity.243
This suggested scheme strikes a good balance for the
incentives to bring patent invalidity challenges. The overall
number of patent challenges will decrease compared to the
current situation in small-molecule drugs. However, it does not
eliminate the incentive to initiate patent-invalidation
challenges, contrary to the current rigid twelve-year FDA
exclusivity. Invalidation challenges will be commenced by FOB
companies in the case that the remaining patent term of the
referenced biologic is longer than the adjudicated market
exclusivity.244 The time difference between the remaining
patent term and the adjudicated market exclusivity provides
the additional profit margin that FOB companies gain by
invalidating the patents.245 If the market exclusivity is equal to
or longer than the remaining patent terms, there is no
incentive for FOB companies to invalidate innovators’ patents
because there is no extra profit margin.246

fda_law_blog_hyman_phelps/2010/02/ogds-anda-backlog-and-median-andaapproval-times-are-up-way-up-the-solution-lies-in-resources-says-f.html
(showing that ANDA median approval time is 26.7 months; approximately two
years). Thus, a reasonable expectation is for an ABLA to be approved within
three to four years.
243. See Karst, supra note 49 (referencing a problem which this suggested
scheme solves). A rigid twelve-year data exclusivity will cause unknown delay,
perhaps stretching far after the expiration of the twelve-year data exclusivity
period. This is because under the suggested scheme, FOB companies can
submit ABLAs at the time the six-year data exclusivity expires and go
through the clinical trial and regulatory review processes while the reference
product market exclusivity is still ongoing. The ABLA approval process of, on
average, three to four years is likely to be finished before, or at least not long
after, the reference product market exclusivity expires.
244. See generally Drug Price Competition and Patent Term Restoration
(Hatch-Waxman) Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as
amended in scattered sections of 15, 21, 28, and 35 U.S.C.). If the patents
covering the reference biologic are invalidated, FOB companies can sell the
competing product at the expiration of the reference biologic’s market
exclusivity. See generally Ware & Littlefield, supra, note 64. If the reference
biologic’s market exclusivity is equal to or longer than the underlying patents,
FOB companies gain nothing by invalidating the patents because the
biosimilar products will not be approved by the FDA until the market
exclusivity expires anyway.
245. See Hemphill & Sampat, supra note 66, at 328 (discussing the process
and incentives for generic drug-makers to challenge patents).
246. Id.

650

MINN. J. L. SCI. & TECH.

[Vol. 15:1

Finally, innovator companies will have a harder time
engaging in evergreening tactics under this scheme.247 During
the trial-type adjudication, the experts from the FTC and the
FDA and advocates from innovator companies will review
factual information and engage in rigorous deliberation. This
deliberation process makes it difficult for innovator companies
to justify evergreening.248
CONCLUSION
Biologics promise cutting-edge therapies treating the
toughest diseases faced in our time.249 In October 2010, the
BPCIA was enacted, establishing an abbreviated approval
pathway for follow-on biologics, known as the biosimilar
pathway.250 Analogous to the Hatch-Waxman Act, the central
mission of the BPCIA is to balance two competing interests:
innovation and accessibility.251 One of the most important
provisions in the BPCIA is 42 U.S.C. § 262(k)(7)(A), which
provides twelve-year FDA exclusivity.252 At the time of this
writing, it remains unclear whether this twelve-year FDA
exclusivity is data or market exclusivity.253 This Note concludes
that this rigid twelve-year FDA exclusivity tips the balance
toward innovation and compromises accessibility.254 To strike a
better balance, this Note proposes a six-year data exclusivity
period and a six-to-twelve-year dynamic market exclusivity

247. See generally id. (presenting responses to evergreening). In the
adjudication process, the innovator companies will submit briefs, present
experts, and orally advocate their positions for a longer period of market
exclusivity. But if the biologic product at issue is a modified version of a
previous product with minor or insignificant safety and efficacy
improvements, the company will have a harder time convincing the expert
panel to grant extra market exclusivity.
248. Id.
249. See Patton, supra note 32.
250. See Biologics Price Competition and Innovation Act of 2009, Pub. L.
No. 111-148, § 7001, 124 Stat. 119, 804 (2010).
251. See id. § 7001(b), 124 Stat. at 804; see also Drug Price Competition
and Patent Term Restoration (Hatch-Waxman) Act of 1984, Pub. L. No.
98-417, 98 Stat. 1585 (codified as amended in scattered sections of 15, 21, 28,
and 35 U.S.C.).
252. See Krauskopf, supra note 46.
253. See Karst, supra note 49 (noting that the Commissioner of the FDA
interpreted the twelve-year FDA exclusivity as a market exclusivity). On the
other hand, some Senators and Representatives interpreted the twelve-year
FDA exclusivity as data exclusivity. Id.
254. See supra Part II.B.3 of this Note for detailed articulations.
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scheme.255 In this scheme, experts from the FTC and the FDA
will individually adjudicate a six-to-twelve-year market
exclusivity period for each innovator biologic to ensure that
innovator companies have a sufficient exclusive period to
recoup their investment.256 This scheme allows ABLAs to be
submitted at the expiration of the six-year data exclusivity
period and allows FOBs to enter the market at or near the
expiration of the market exclusivity period.257 The scheme
reduces, yet does not eliminate, the incentives to challenge
innovators’ patents.258 Finally, the scheme has the potential to
halt evergreening.259 Thus, this regulatory scheme with sixyear data exclusivity and six-to-twelve-year dynamic market
exclusivity strikes a better balance between innovation and
accessibility.

255. See supra Part II.D of this Note for detailed articulations.
256. See supra Part II.D.
257. See Karst, supra note 49.
258. See Drug Price Competition and Patent Term Restoration (HatchWaxman) Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended
in scattered sections of 15, 21, 28, and 35 U.S.C.).
259. See generally Hemphill & Sampat, supra note 66.
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